Kadimastem Granted a Patent in Israel for the Treatment of ALS

Specifically, the patent allows for the innovative method of non-genetically modifying a cell population of human progenitor astrocytes or astrocytes, for use in the treatment or prevention of the progression of ALS in a human subject in need and screening an agent for preventing or treating Amyotrophic Lateral Sclerosis (ALS) by using this cell population.

Kadimastem’s flagship product, AstroRx®, is comprised of a differentiated cell population of human astrocytes derived from human pluripotent stem cells and is in clinical development as a therapeutic treatment for ALS. Kadimastem recently announced encouraging results of the Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS. See press release here.

The technology was first initiated at the Weizmann Institute of Science while Professor Michel Revel, the co-founder of Kadimastem, was a principal investigator there. It continues to be developed by the experienced and dedicated team in the laboratories of Kadimastem, where Professor Revel serves as the Chief Scientific Officer.

Kadimastem CEO Asaf Shiloni said, "The patent granted by the Israel Patent Office is a significant step forward towards bringing AstroRx® to market for the benefit of ALS patients worldwide. We aim to have a pre-IND meeting with the US FDA in the near future, with the goal of setting in motion the next stage of clinical trials as soon as possible. In the meantime, we shall continue our groundbreaking research and development programs for both our ALS and diabetes products.”

Kadimastem Chief Scientific Officer Professor Michel Revel added, "Israel is an important market for research and development and for setting international medical standards and precedent. Today’s patent is an important milestone that supports producing the cells for AstroRx® in Israel for use worldwide."